Lyme Disease Vaccine: History, Current Status, and Future Prospects

LYMErix: The First Lyme Vaccine (1998–2002)

• Target: OspA protein on Borrelia burgdorferi in tick midgut; antibodies ingested by feeding tick kill bacteria before transmission.
• Efficacy: ~76% after 3 doses (0, 1, 12 months) in trials.
• Withdrawal: 2002 – GlaxoSmithKline cited declining sales amid:
  • Class-action lawsuits claiming arthritis (later refuted by FDA/VAERS).
  • Anti-vaccine activism.
  • Complex dosing schedule.
  • Uncertainty about booster needs.

Current US Status

No human Lyme vaccine is currently available in the US. Prevention relies on:

• Tick avoidance (permethrin-treated clothing, DEET/picaridin repellents).
• Daily tick checks; prompt removal (<24 hrs attachment = low transmission risk).
• Single-dose doxycycline prophylaxis (within 72 hrs of high-risk bite in endemic areas).

Vaccines in Development

• VLA15 (Valneva/Pfizer): Multivalent OspA (covers 6 serotypes). Phase 3 ongoing (NCT05477524); potential approval 2025–2026.
• mRNA approaches: Moderna, others in preclinical.
• Chimeric vaccines: Targeting multiple Borrelia species (Europe/Asia).

International Availability

Some European countries (Austria, Germany) have licensed vaccines (e.g., FSME-IMMUN for TBE, not Lyme). No widely available Lyme vaccine outside trials currently.

Consult your physician for latest recommendations; tick-bite prophylaxis remains standard of care.